Vitamin D deficiency and effect of treatment on seizure frequency and quality of life parameters in patients with drug‐resistant epilepsy: A randomized clinical trial

Author:

Chassoux Francine1,Navarro Vincent2ORCID,Quirins Marion3,Laurent Agathe1,Gavaret Martine45,Cousyn Louis2ORCID,Crépon Benoit4,Landré Elisabeth1,Marchi Angela4,Soufflet Christine4,Rusu‐Devaux Violeta4,Mancusi Rossella Letizia6,Piketty Marie‐Liesse7,Souberbielle Jean‐Claude7

Affiliation:

1. Department of Neurosurgery, Groupe Hospitalier Universitaire Paris Psychiatry and Neurosciences Paris France

2. Epilepsy Unit, Pitié‐Salpêtrière Hospital and Paris Brain Institute Assistance Publique Hopitaux de Paris, Sorbonne University Paris France

3. Department of Neurology Bicêtre Hospital Le Kremlin‐Bicêtre France

4. Department of Clinical Neurophysiology Groupe Hospitalier Universitaire Paris Psychiatry and Neurosciences Paris France

5. Institute of Psychiatry and Neuroscience of Paris Université Paris Cité, INSERM UMR 1266 Paris France

6. Direction of Clinical Research and Innovation, Groupe Hospitalier Universitaire Paris Psychiatry and Neurosciences Paris France

7. Department of Functional Explorations, Necker Hospital Paris France

Abstract

AbstractObjectiveThis study was undertaken to assess the effect of treatment of vitamin D deficiency in drug‐resistant epilepsy.MethodsWe conducted a multicenter, double‐blind, placebo‐controlled, randomized clinical trial, including patients aged ≥15 years with drug‐resistant focal or generalized epilepsy. Patients with 25‐hydroxyvitamin D (25[OH]D) < 30 ng/mL were randomized to an experimental group (EG) receiving vitamin D3 (cholecalciferol, 100 000 IU, five doses in 3 months) or a control group (CG) receiving matched placebo. During the open‐label study, EG patients received 100 000 IU/month for 6 months, whereas CG patients received five doses in 3 months then 1/month for 3 months. Monitoring included seizure frequency (SF), 25(OH)D, calcium, albumin, creatinine assays, and standardized scales for fatigue, anxiety–depression, and quality of life (Modified Fatigue Impact Scale [M‐FIS], Hospital Anxiety and Depression Scale, Quality of Life in Epilepsy [QOLIE‐31]) at 3, 6, and 12 months. The primary efficacy outcome was the percentage of SF reduction compared to the reference period and CG at 3 months. Secondary outcomes were SF and bilateral tonic–clonic seizure (BTCS) reduction, scale score changes, and correlations with 25(OH)D during the follow‐up.ResultsEighty‐eight patients were enrolled in the study (56 females, aged 17–74 years), with median baseline SF per 3 months = 16.5 and ≥2 antiseizure medications in 88.6%. In 75 patients (85%), 25(OH)D was <30 ng/mL; 40 of them were randomly assigned to EG and 34 to CG. After the 3‐month blinded period, SF reduction did not significantly differ between groups. However, during the open‐label period, SF significantly decreased (30% median SF reduction, 33% responder rate at 12 months). BTCSs were reduced by 52%. M‐FIS and QOLIE‐31 scores were significantly improved at the whole group level. SF reduction correlated with 25(OH)D > 30 ng/mL for >6 months.SignificanceDespite no proven effect after the 3‐month blinded period, the open‐label study suggests that long‐term vitamin D3 supplementation with optimal 25(OH)D may reduce SF and BTCSs, with a positive effect on fatigue and quality of life. These findings need to be confirmed by further long‐term studies.Trial RegistrationClinicalTrials.gov identifier: NCT03475225 (03‐22‐2018).

Publisher

Wiley

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3